Lantheus HoldingsSTU:0L8 -0.97%86 OCF Yield % is 5.97 as of Jun. 25, 2026, which is 19% below its 10-year median of 7.38. GuruFocus rates STU:0L8 with a GF Score™ of 86/100 and a GF Value™ of €79.94 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Lantheus Holdings ranks better than 64.18% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Lantheus Holdings OCF Yield % Related Terms
Lantheus Holdings OCF Yield % Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0L8 vs HIMS, ALKS, LQDA: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (STU:0L8) has a OCF Yield % of 5.97 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Lantheus Holdings and its competitors. This is 19% below median its historical median of 7.38. Over the past decade, Lantheus Holdings' OCF Yield % has ranged from 0.91 to 31.20. According to the industry distribution chart, Lantheus Holdings ranks #360 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 35.8%.
Is Lantheus Holdings' OCF Yield % too high?
Lantheus Holdings' current OCF Yield % of 5.97 is 19% below median its 10-year median of 7.38. Over the past 10 years, this metric has ranged from a low of 0.91 to a high of 31.20. The Drug Manufacturers industry median OCF Yield % is 3.57. Lantheus Holdings' value of 5.97 is 67.2% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #360 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lantheus Holdings has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' OCF Yield % compare to HIMS and ALKS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #360 out of 1005 companies for OCF Yield %. This puts Lantheus Holdings in the upper half of its industry. The industry median OCF Yield % is 3.57. Lantheus Holdings' value of 5.97 is 67.2% above this benchmark. Historically, Lantheus Holdings' own OCF Yield % has ranged from 0.91 to 31.20 over the past decade. While the company's 10-year median is 7.38 vs. the industry median of 3.57, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.57, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current OCF Yield % of 5.97 is 67.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current OCF Yield % is 5.97, which is 19% below median its own 10-year median of 7.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (STU:0L8) is currently considered Modestly Overvalued. The stock's GF Value™ is €79.94, compared to a current price of €92.30 — trading 15.5% above its estimated fair value. The current OCF Yield % is 5.97, which is 19% below median its 10-year median of 7.38 and 67.2% above the Drug Manufacturers industry median of 3.57. Lantheus Holdings' overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Lantheus Holdings (STU:0L8), the current OCF Yield % is 5.97 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (STU:0L8) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of €92.30 is trading 15.5% above its estimated GF Value™ of €79.94.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for STU:0L8:
OCF Yield %: 5.97 (19% below median its 10-year median of 7.38)
GF Value™: €79.94 vs. price of €92.30 (15.5% above fair value)
Industry Position: 67.2% above the Drug Manufacturers median (#360 of 1005)
No single metric tells the full story. See the STU:0L8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
86GF Score
Get the complete analysis for STU:0L8
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0L8 has been successfully added to your 
